<DOC>
	<DOCNO>NCT02605590</DOCNO>
	<brief_summary>This study perform assess safety , tolerability PK escalate inhale AIR-DNase dos administer single dose follow multiple dos 5 consecutive day healthy subject . A thorough review safety data conduct completion dose level per subject prior , move next dose level Part 1 commencement multiple dose Part 2 .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Study AIR DNAse Administered Inhalation Healthy Adult Volunteers</brief_title>
	<detailed_description>This Phase I study evaluate safety , tolerability pharmacokinetics inhale AIR DNase healthy volunteer . Up 18 healthy male subject ( age 18 -55 inclusive ) randomize one three dose cohort ( 6 subject per cohort ) , receive AIR DNase dose equivalent 1.25 mg , 2.5mg 5 mg placebo accordance . Subjects randomize one cohort receive either active placebo single dose , continuation , follow safety assessment , receive multiple dos , daily 5 consecutive day . Subjects remain clinical center 8 hour single administration AIR DNase/placebo include PK sampling . During multiple dose subject arrive clinical center daily AIR DNase/placebo administration study procedure remain site 4 hour post dose . Follow visit perform 7±2 day follow single administration 7±2 day follow last administration multiple phase .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Subject understands study procedure provide write informed consent participate study . 2 . Healthy , male , 1855 year age , inclusive 3 . Non smoker , declaration , least 6 month prior screen 4 . Body mass index ( BMI ) ≥ 18.5 ≤ 29.0 kg/m2 screening . 5 . Healthy individual clinically significant finding : medical history , physical examination , laboratory profile , vital sign , 12lead ECG 6 . Spirometry result within normal range . 7 . A subject , whose female copartner childbearing potential , must agree use two medically acceptable method contraception throughout study . 1 . History asthma , chronic pulmonary disease , recurrent pneumonia , allergic rhinitis . 2 . History illness medical condition ( include psychiatric ) might confound result study pose additional risk subject participation study . 3 . Any acute illness ( e.g . acute infection ) within 48 hour prior study drug administration , consider significance Investigator . 4 . Known contraindication , hypersensitivity and/or allergy drug . 5 . History adverse reaction aerosol delivery medicinal product . 6 . History presence alcoholism drug abuse within past 2 year prior screen . 7 . Positive urine drug abuse test result prior first dosing . 8 . Positive breath alcohol test admission CRC prior first dose . 9 . Positive result screen HIV , HBsAg , HCV Ab . 10 . Sitting blood pressure le 90/40 mmHg great 140/90 mmHg screening . 11 . Sitting heart rate lower 45 beat per minute ( bpm ) high 99 bpm screening . 12 . Use prescription overthecounter medication , include vitamin , herbal , dietary supplement within 14 day prior dose . Paracetamol , 2g /day allow 24 hour prior dose . 13 . Donation blood within 90 day prior dose . 14 . Donation bone marrow within last 6 month prior dose . 15 . Participation another clinical trial within 90 day prior dose study drug administer . 16 . Subject mentally legally incapacitated significant emotional problem unable communicate well investigator CRC staff ( i.e. , language problem , poor mental development impair cerebral function ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>